Identification of deactivation procedure for Trilaciclib
Department of pharmacy; Sri Satya Sai University of Technology and Medical Sciences, Sehore, India.
Research Article
World Journal of Advanced Research and Reviews, 2022, 15(03), 467–472
Publication history:
Received on 25 August 2022; revised on 27 September 2022; accepted on 30 September 2022\
Abstract:
The Indian health-care facilities (HCFs) made some guidelines related to cytotoxic drugs so called cytotoxic policy for patient safety and health-care worker safety, and environmental monitoring program as per the available international guidelines. Trilaciclib is indicated for the treatment of patients with multiple myeloma and chemically it is a tetra peptide epoxy ketone and an analog of epoxomicin. Analytical method for the detection of Deactivating agent and concentration play an impartment role in the pharmaceuticals especially with cytotoxic molecules after completion of manufacturing and testing is mandatory to follow the safety protocol to dispose those materials. The present invention provides to identify the suitable deactivating agent for the neutralization of Trilaciclib injection 10 mg/mL and Trilaciclib API with respect to concentration and time. This method developed based by RP-HPLC.
Keywords:
Trilaciclib; Deactivating Agent; Sodium Hypochlorite Solution; Parenteral dosage form; RP-HPLC; Cytotoxic waste
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0